Written questions by Mierlo.

On what date he expects the final report of the independent ADHD taskforce to be published.

The ADHD taskforce's final report is expected to be published later this year.

How many patients have accessed Vamorolone since it was given NICE approval for Duchenne Muscular Dystrophy; what assessment he has made of the adequacy of availability of Vamorolone to patients with DMD in that period; and whether the NHS had fully implemented the NICE recommendation by the April 2025 deadline.

The National Institute for Health and Care Excellence (NICE) published its technology appraisal, titled Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over, on 16 January 2025. NHS England routinely commissioned vamorolone in line with the guidance, from 16 April 2025.When a patient is started on vamorolone, the prescribing clinician submits an electronic prior approval form, confirming that NICE’s recommendation criteria are met. NICE’s costing report, included in the technology appraisal, suggested that 1,390 people expected to receive vamorolone in 2025/26. The NICE’s technology appraisal is available at the following link:https://www.nice.org.uk/guidance/ta1031/resources/resource-impact-summary-report-15239352925/chapter/Resource-impact-summary-reportThere is only 10 full weeks of data available since routine commissioning commenced in mid-April, and over this period there have been 32 prior approval forms submitted. Whilst submission of a form is not confirmation that treatment has begun, this is used as a proxy indication for the number of patients starting treatment.

Whether he has made an assessment of the adequacy of the provision of 24/7 palliative care in Oxfordshire: and what steps he is taking to extend provision of this service.

We want a society where every person receives high-quality, compassionate care from diagnosis through to the end of life. The Government will shift the focus of healthcare out of the hospital and into the community, to ensure patients and their families receive personalised care in the most appropriate setting. Palliative care and end of life care services will have a big role to play in that shift.Palliative care services are included in the list of services that integrated care boards (ICBs), including the NHS Buckinghamshire, Oxfordshire and West Berkshire ICB, must commission. This promotes a more consistent national approach and supports commissioners in prioritising palliative care and end of life care. To support ICBs in this duty, NHS England has published statutory guidance and service specifications, with further information on both available, respectively, at the following two links:https://www.england.nhs.uk/publication/palliative-and-end-of-life-care-statutory-guidance-for-integrated-care-boards-icbs/https://www.england.nhs.uk/publication/service-specifications-for-palliative-and-end-of-life-care-adults/The statutory guidance makes specific reference to commissioners defining how their services will meet population needs 24/7 and includes a priority action for ensuring that staff, patients, and carers can access the care and advice they need, whatever time of day.Earlier this year, I met with key palliative care and end of life care and hospice stakeholders, in a roundtable format, with a focus on long-term sector sustainability within the context of our forthcoming 10-Year Health Plan.

What assessment he has made of the merits of reforming GP licensing; and whether he will make it his policy to protect GPs from unaffordable costs when a practice fails financially.

Most general practices (GPs) are run by general, unlimited liability partnerships. Limited liability partnerships are currently not permitted as business vehicles for General Medical Services or Personal Medical Services contractors. However, limited companies can be used to manage financial risks in a partnership. GP partnerships may also manage liabilities through indemnities and different forms of insurance. As independent contractors and small business owners, these are decisions for GP partners to make, with legal and accounting advice.We have committed to substantive GP Contract reform within this Parliament following acceptance of the 2025/26 contract by the General Practitioners Committee England. As part of this, we expect to consider a breadth of topics, which may include updates to the partnership model.We are investing an additional £889 million in GPs, to reinforce the front door of the National Health Service and to bring back the family doctor, bringing the total spend on the GP Contract to £13.2billion in 2025/26. This is the biggest increase in over a decade, and means we are reversing the recent trend by allocating a rising share of total NHS resources to GPs.

What criteria his Department has used to determine the allocation of repair funds to the Royal Berkshire Hospital.

The £750 million Estates Safety Fund is part of the overall 2025/26 capital allocation announced by the Chancellor at the Autumn Budget 2024.The £750 million was divided between integrated care systems (ICSs) through indicative funding allocations as part of the NHS Capital Guidance 2025/26. Each system’s indicative allocation represents a proportion of the £750 million based on need, taking into account levels of critical infrastructure risk, incidents and returns to the recent maternity estates survey.Due to the diverse needs of the National Health Service estate, a flexible approach has been taken to ensure national and regional priorities are addressed effectively. ICSs worked with their local systems to identify and prioritise which schemes would be funded at which sites from their provisional allocations to deliver maximum safety benefits. The value of these schemes determined the financial allocations to NHS trusts.

What assessment he has made of the potential merits of reforming GP licensing; and if he will develop plans to protect GPs from costs when practices fail financially.

We have committed to substantive GP contract reform within Parliament following acceptance of the 2025/26 contract by the England general practitioners committee of the British Medical Association. As part of this, we expect to consider a breadth of topics, which may include updates to the partnership model.Practices with a General Medical Services contract are eligible for rent reimbursements, with different terms depending on the ownership or occupation arrangements for the property, as set out in the Premises Costs Directions 2024. The commissioner has discretion to provide further financial assistance if other costs rise exponentially, such as service charges, all budget-dependent.

What steps he is taking to ensure that private providers of physiotherapy services to the NHS (a) provide value for money and (b) do not operate with excessive profit margins.

Throughout its history, the National Health Service has always worked with non-NHS healthcare providers to deliver essential services to patients, especially at times of operational pressures. The overall proportion of health spending on independent sector providers has not increased significantly over recent years. In 2013/14, 6.1% of total health spending, or £6.5 billion, was spent on purchase of healthcare from independent sector providers. In 2023/24, this was 6.8% or £12.4 billion.The Provider Selection Regime is a set of rules for procuring health care services in England, giving decision-makers the flexibility they need to arrange services that best promote the interests of patients, the taxpayer, and the population. As part of the Provider Selection Regime, commissioners need to be transparent in their decision making to ensure that there is proper scrutiny and accountability of decisions made about NHS services.Rates of payment for physiotherapy services are set at a local level. Pursuant to the Government’s public interest test, NHS bodies are not obliged to accept any bids submitted by external suppliers unless they clearly demonstrate value for money and deliver against the aims and objectives of a business cases. It is expected that any outsourced services are delivered in a way that improves quality, ensures greater stability and longer-term investment in the workforce, and delivers better value for money as part of broader commitments on procurement.

What assessment he has made of the adequacy of (a) funding and (b) the availability of trained staff for GP practices to perform blood tests for children.

Overall, ensuring adequate general practice (GP) provision is the responsibility of the integrated care boards (ICBs).GPs are independent businesses, providing primary care services, based on a National Health Service GP Contract, to their local populations. Most commonly, GPs are run by GP partners who, alongside other GPs and healthcare staff, are responsible for running their own practice. This allows them to have relative autonomy in deciding how to provide contracted services, and provides opportunities for innovation.Local enhanced services, such as blood tests, are negotiated and agreed locally, and are commissioned by ICBs to fit the needs of the local population. GPs can choose whether or not they would like to participate in providing these services. These services can vary in scope and funding across the country.

What assessment he has made of the adequacy of the availability of phlebotomy services to perform blood tests for children in (a) Oxfordshire and (b) nationally.

The Government is committed to putting patients first. This means making sure that patients are seen on time and ensuring that patients have the best possible experience during their care.Community diagnostic centres (CDCs) offer local populations a wide range of diagnostic tests closer to home as well as greater choice on where and how they are undertaken. This reduces the need for hospital visits, reduces pressure on hospitals, and speeds up diagnosis. CDCs are expected to offer their services to children and young people where it is safe and appropriate to do so. The Oxfordshire, Oxford CDC in Cowley delivers a range of diagnostic services, including phlebotomy services.Phlebotomy services are also provided by general practices (GPs). Where services are provided by GP, they are commissioned locally by integrated care boards (ICBs), based on local population need, and are funded as part of their annual funding allocations.In Oxfordshire, the Buckinghamshire, Oxfordshire and Berkshire West ICB has commissioned GPs to deliver phlebotomy services for all ages, including children. Services must be led by suitably trained professionals.Guidance communicated to GPs from the Berks, Bucks and Oxon Local Medical Committee, the body representing all NHS GPs practising in the Buckinghamshire, Oxfordshire, and Berkshire area, is that GPs should not perform blood tests for patients under 12 years old and instead that these should be performed by specialist paediatric trained staff. Where GPs have clinical staff with the training, competence, and experience to perform blood tests on patients under 12 years old, these services may be available. However, at practices that do not have these staff, they will instead refer the child to alternative providers, such as in a children’s hospital clinic.

What steps he is taking to encourage Hormone Replacement Therapy implant manufacturers to apply for UK licenses.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the Department have kept ministers informed of the ongoing issues in the manufacturing of unlicenced products used as medicines for hormone replacement therapy (HRT) implants.Regular discussions with the importer of the unlicenced medicines have been held, and the Medicines Supply team in the Department are actively looking at both licenced and other sources, to ensure an ongoing supply of appropriate products.The MHRA welcomes these applications and has processes in place to review applications for HRT implants, as soon as they are received.

What discussions he has had with the Medicines and Healthcare products Regulatory Agency on encouraging manufacturers to apply for UK licenses for Hormone Replacement Therapy implants.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the Department have kept ministers informed of the ongoing issues in the manufacturing of unlicenced products used as medicines for hormone replacement therapy (HRT) implants. Regular discussions have been held with the importer of the unlicenced medicines, and the Medicines Supply team in the Department are actively looking at licenced alternatives to ensure ongoing supply.A medicine can only become licensed if an application is made for such a licence, usually by the manufacturer, and the MHRA is only able to grant a marketing authorisation after the supporting data has been assessed to demonstrate its quality, safety, and efficacy for the conditions it is intended to treat, and to confirm that it has an acceptable balance of risk and benefit. In our role as the medicines regulator, we are not in a position to solicit for new product licence applications.However, the MHRA welcomes marketing authorisation applications for HRT implants and has processes in place to review applications as soon as they are received. In addition, manufacturers can seek scientific advice on their product from the MHRA at any stage of development.

What steps he is taking to ensure access to licenced Hormone Replacement Therapy implants for women.

There are currently no licensed United Kingdom suppliers of oestrogen and testosterone hormone replacement therapy (HRT) implants in the UK, and companies are free to decide what they market.The Department is working closely with the Medicines and Healthcare products Regulatory Agency to ensure safe access to these products. As part of this, we have also reached out to specialist importers who can source unlicensed medicines in order to find HRT implants for UK patients.

If he will make an assessment of the potential merits of expanding the criteria for medical exemption certificates to include everyone with a (a) disability and (b) chronic illness.

The Department has no plans to expand the criteria for medical exemption certificates.Individuals with qualifying medical conditions or with a continuing physical disability which prevents them from leaving their residence without the help of another person are entitled to apply for a medical exemption certificate.People may also be exempt from prescription charges depending on their age, whether they are in qualifying full-time education, whether they are pregnant or have recently given birth, or whether they are in receipt of certain benefits or a war pension.People who do not qualify for an exemption and who need many prescription items could save money with a prescription prepayment certificate, which allows people to claim as many prescriptions as they need for a set cost. People on a low income can seek help under the NHS Low Income Scheme.

If he will make it his policy to review the adequacy of the earnings criteria for free prescriptions.

No discussions have been held between my Rt Hon. Friend, the Secretary of State for Health and Social Care and my Rt Hon. Friend, the Secretary of State for Work and Pensions on expanding eligibility to all claimants in receipt of Universal Credit. The Department keeps the earnings thresholds for free prescriptions under review on an annual basis.Approximately 89% of prescription items dispensed in community pharmacy in England are free of charge, and for the first time in three years prescription charges have been frozen, meaning around 40% of the population will save money on their prescriptions.

What discussions he has had with the Secretary of State for Work and Pensions on the potential merits of expanding eligibility for free prescriptions to include everyone in receipt of Universal Credit.

No discussions have been held between my Rt Hon. Friend, the Secretary of State for Health and Social Care and my Rt Hon. Friend, the Secretary of State for Work and Pensions on expanding eligibility to all claimants in receipt of Universal Credit. The Department keeps the earnings thresholds for free prescriptions under review on an annual basis.Approximately 89% of prescription items dispensed in community pharmacy in England are free of charge, and for the first time in three years prescription charges have been frozen, meaning around 40% of the population will save money on their prescriptions.

If he will make an assessment of the potential merits of using (a) PET scans, (b) cerebrospinal fluid testing and (c) other bio-marker led tests to confirm Alzheimer's disease.

The Department delivers dementia research through the National Institute for Health and Care Research (NIHR). The NIHR funds a range of research into dementia, for example investing almost £11 million to develop new digital approaches for the early detection and diagnosis of dementia.The Government’s Dame Barbara Windsor Dementia Goals programme has already invested £13 million into a range of biomarker innovation projects which include biomarker technologies, ranging from an artificial intelligence tool designed to improve the accuracy of blood tests for dementia, to using retinal scans to detect early-onset dementia decades before symptoms. Some of these innovations could support improved diagnosis in the future, if validated for clinical use.

What steps he is taking to increase the proportion of Alzheimer's disease specialists compared to other G7 countries.

The provision of dementia health care services is the responsibility of local integrated care boards (ICBs). We expect ICBs to commission services based on local population needs, taking account of National Institute for Health and Care Excellence guidelines.We want all health and care staff to have received appropriate training to provide high quality care to people with dementia. Employers in the health system are responsible for ensuring that their staff are trained to the required standards to deliver appropriate care for patients. The required training needs are set out in the Dementia Training Standards Framework, which is available through Skills For Health at the following link:https://www.skillsforhealth.org.uk/wp-content/uploads/2021/01/Dementia-Core-Skills-Education-and-Training-Framework.pdf

What steps he is taking to help support UK-based research into new forms of treatment for dementia.

The Department delivers dementia research via the National Institute for Health and Care Research (NIHR). Government funders are investing in dementia research across all areas, from causes, diagnosis and prevention to treatment, care and support, including for carers.The NIHR is investing almost £50 million to the UK Dementia Trials Network, which will deliver a coordinated network of early phase dementia trial sites. This will be complemented by the £20 million Dementia Clinical Trials Accelerator, designed to position the United Kingdom as the destination of choice for late phase clinical trials in dementia and neurodegenerative diseases.The NIHR welcomes funding applications for research into any aspect of human health and care, including dementia. These applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money and scientific quality. Welcoming applications on dementia to all NIHR programmes enables maximum flexibility both in terms of amount of research funding a particular area can be awarded, and the type of research which can be funded.The Government’s Dame Barbara Windsor Dementia Goals programme, with almost £150 million expected to be allocated to, or aligned with it, aims to speed up the development of new treatments for dementia by accelerating innovations in biomarkers, clinical trials and implementation. Some of this will be delivered through the Neurodegeneration Initiative which the programme is establishing, which will be a globally unique, not-for-profit, industry led public-private partnership that will work together across government, industry, academia, the National Health Service and third sector to deliver its objectives, including UK research organisations.So far, the programme has invested £13 million into a range of biomarker innovation projects, many of which are being delivered by UK small and medium enterprises and UK research organisations.

What steps he is taking to return the dementia diagnosis rate to its target level.

To support recovery of the dementia diagnosis rates, we have developed a memory service dashboard to support commissioners and providers with appropriate data and enable targeted support where needed.We have funded an evidence-based improvement project to fund two trusts in each region, totalling 14 sites, to pilot the Diagnosing Advanced Dementia Mandate protocol. Learning is currently being shared and promoted with regional and local partners following an impact assessment of the pilots.The Office for Health Improvement and Disparities’ Dementia Intelligence Network has developed a tool for local systems to enable investigation into local variation in diagnosis and take informed action to enhance diagnosis rates.We have also published the D100: Assessment Tool Pathway programme, which brings together multiple resources into a single, consolidated tool. The tool continues the work of the Dementia Care Pathway, covering all elements of the Well Pathway, including Diagnosing Well.The D100: Pathway Assessment Tool launched in April 2025 and is available at the following link:https://www.rcpsych.ac.uk/improving-care/nccmh/service-design-and-development/dementia-100-pathway-assessment-tool

If he will make an assessment of the potential impact of the time taken by integrated care boards to add new National Institute for Health and Care Excellence-recommended medicines to their formularies on the ability of NHS patients to access new treatments.

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an assessment of their costs and benefits. The NHS in England is legally required to fund medicines recommended in a NICE technology appraisal, usually within three months of final guidance.The NICE has published guidance on the adoption of medicines in local formularies which states that once a NICE technology appraisal recommends a medicine, it must be included in a local formulary within three months, providing it is clinically appropriate and relevant to the services provided by the organisation, or within 30 days for Early Access to Medicines Scheme medicines.As part of the commitments made in the 2024 voluntary scheme for branded medicines pricing, access and growth (2024 VPAG), NHS England agreed to the development of a local formulary national minimum dataset within the first half of the 2024 VPAG, to increase visibility of local variation in the implementation of NICE guidance, identify where variation in local formularies may be creating barriers to access, and to confirm to NHS England when a NICE recommended treatment has been placed on a local formulary.NHS England also agreed to use the dataset to inform a report, which will be published no less frequently than annually, identifying unwarranted variation between national guidance and local formularies.